Aaron Devanathan

PharmD, PhD, AAHIVP

Clinical and Pharmaceutical Scientist in the HIV/AIDS research space. Views are my own.

[Aaron Devanathan @therealDL144]

Excited to share our publication https://t.co/7qM0xUogbT with @Tom_Nolin (https://t.co/cHP2wJT6nF) and the @RustbeltCFAR about quantifying plasma concentrations of lenacapavir! Plenty of fun #lenacapavir clin PK studies to occur at @pittpharmacy! @GileadSciences @GileadHIV

[ACCP @ACCP]

The Department of Pharmacy & Therapeutics of the University of Pittsburgh School of Pharmacy is accepting applications for a full-time tenured professor and department chair. Apply here: https://t.co/WvSY53Q2d5

#PharmacyJobs #ACCPCareerCenter

[Pitt Pharmacy School @pittpharmacy]

Continuing our Spotlight Series, congrats to Dr. Aaron Devanathan, who was selected to attend the Society of Research Administrators International PI Intensive for New Faculty & Researchers! The Devanathan laboratory focuses on the clinical pharmacology of antiretrovirals. H2P!

[ACCP @ACCP]

The University of Pittsburgh School of Pharmacy Department of Pharmacy & Therapeutics is accepting applications for a full-time tenured professor and department chair. Learn more and apply: https://t.co/MLPgevBV0F

#ClinicalPharmacyJobs #PharmacyCareers #ACCPCareerCenter

[Aaron Devanathan @therealDL144]

It's an exciting time! And even more excited to share that I'm recruiting for a clinical pharmacology fellowship in the HIV/AIDS therapeutic area! Check out the link below and feel free to reach out to me if you have any questions. Feel free to share! https://t.co/3s66kqEjxq

[Aaron Devanathan @therealDL144]

Rome wasn't built in a day...and neither was the #AntiviralPK workshop! Congratulations to Mattia Berton for Best Abstract Award! What a great meeting and can't wait until next year in...Liverpool!!! Thank you all and to @Academic_MedEdu @AlicePharmd @KimScarsi

[Aaron Devanathan @therealDL144]

Does tissue pharmacology matter? Dr. Saye Khoo at #AntiviralPK provided a comprehensive analysis of PK/PD in the tissues. This is a large and complex topic so huge kudos for the overview. Many more questions remain, especially as we enter a new era in ART!

[Aaron Devanathan @therealDL144]

The issues are the tissues! Dr. Charles Flexner at the #AntiviralPK workshop discussed the knowledge gaps related to tissue-specific pharmacology. By using LSD and sildenafil as pharmacological examples, we have learned the tissue-specific PK/PD may not be reflected in plasma.

[Aaron Devanathan @therealDL144]

Examining RMD for HIV-1 latency and its PK endpoints? We learned in an abstract presentation at #AntiviralPK from @CPACLab through a comprehensive dose fractionation study that time correlates with HIV transcription. In the hollow fiber model, Time>EC90 correlated as well.

[Aaron Devanathan @therealDL144]

NMV/r with MPV for COVID in saliva, tear, and nasal was discussed at #AntiviralPK. The AGILE CST-8 study noted NMV penetrates into tears and nasal compartments and aligned well with previous studies. 100% of tear and nasal concentrations were above PK thresholds. BOLO for more!

[Aaron Devanathan @therealDL144]

PrEP in TGW in blood and rectum was the subject of an abstract presentation at #AntiviralPK from @CPACLab. FHT may alter PrEP PK and in this study, FHT hadn't decreased pooled TFV or FTC in either blood or rectum and estradiol wasn't correlated with PrEP concentrations.

[Aaron Devanathan @therealDL144]

Blood sampling devices are not created equal, as discussed during an abstract presentation at #AntiviralPK from @CPACLab. Although inconsistent sponge filling was observed among devices, there had been good agreement with DBS and devices. Device testing before studies is key.

[Aaron Devanathan @therealDL144]

Concluding our industry session at #AntiviralPK is Dr. Xiao-Jian Zhou at @ateapharma discussing bemnifosbuvir for HCV! Bemnifosbuvir has dual activity against HCV (in combo with ruzasvir) and COVID, and these studies are ongoing. BOLO for more info on these antivirals!

[Aaron Devanathan @therealDL144]

Continuing the industry session at #AntiviralPK is Dr. Simon Portsmouth at @SHIONOGI_JP to discuss the development of antivirals for influenza and SARS-Cov-2! We learned about the clinical and virologic outcomes and the PK properties of these newer antivirals.

[Aaron Devanathan @therealDL144]

Next up in the industry session at #AntiviralPK is Dr. Jon Collins from @ViiVHC @ViiVUS to provide insight into the drug pipeline! Long-acting and ultra-LA, new classes of ARVs, new formulations of current ARVs, antibody therapies, complex PK properties, oh my!

[Aaron Devanathan @therealDL144]

Welcome to Day 3 of the #AntiviralPK workshop! Starting us off is Dr. Ramesh Palaparthy from @GileadSciences to discuss long-acting therapies! We learned the lore and development of lenacapavir, its properties suitable for long-acting formulations, and its PK profiles.

[Aaron Devanathan @therealDL144]

NMV/r and anticoagulants...what's the deal? At #AntiviralPK, an abstract presentation discussed the safety and management of these DDIs in ambulatory settings. 11 patients had changes to anticoag tx, either a dose decrease or an alternative agent with no reports of TE events.

[Aaron Devanathan @therealDL144]

NMV/r DDIs with anticancer drugs are understudied and at #AntiviralPK, real-world management of NMV/r with systemic cancer tx was discussed in an abstract presentation. There were 40 instances of clinically significant DDIs and increased potential for toxicity of cancer tx.

[Aaron Devanathan @therealDL144]

Continuing the NMV/r discussion at #AntiviralPK, an abstract presentation discussed the real-world DDI management with co-medications. 184 total DDIs were flagged, and more will be reported with greater adoption. Having these systems is important for clinical decision-making.

[Aaron Devanathan @therealDL144]

Teamwork makes the dream work! Dr. Alice Pau from the @NIH at #AntiviralPK discussed the history and lore of the Cross-Atlantic Collaboration to standardize DDI management with nirmatrelvir/r. Given more widespread use and comorbidities, this was an urgent matter.